Download Files:

Pomalidomide-PEG1-C2-N3

$185

Only 1000 item(s) left in stock.

Products Details

Product Description

– Pomalidomide-PEG1-C2-N3 is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and 1-unit PEG linker used in PROTAC technology. Pomalidomide-PEG1-C2-N3 can be used to design a selective CDK6 PROTAC degrader CP-10. CP-10 induces the degradation of CDK6 with an DC50 of 2.1 nM[1]. Pomalidomide-PEG1-C2-N3 is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. Strain-promoted alkyne-azide cycloaddition (SPAAC) can also occur with molecules containing DBCO or BCN groups.

Web ID

– HY-125843

Storage Temperature

– -20°C (Powder, stored under nitrogen)

Shipping

– Blue Ice

Applications

– Cancer-programmed cell death

Molecular Formula

– C17H18N6O5

References

– [1]Su S, et al. Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. J Med Chem. 2019 Aug 2.

CAS Number

– 2271036-44-1

Molecular Weight

– 386.36

Compound Purity

– 99.91

SMILES

– O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3NCCOCCN=[N+]=[N-])=O

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– E3 Ligase Ligand-Linker Conjugates

Isoform

– Cereblon

Pathway

– PROTAC

Product type

– Reference compound

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.